Advanced Oncotherapy (FRA:R3I1) Total Stockholders Equity : €70.51 Mil (As of Jun. 2022)

View and export this data going back to 2018. Start your Free Trial

What is Advanced Oncotherapy Total Stockholders Equity?

Advanced Oncotherapy's Total Stockholders Equity for the quarter that ended in Jun. 2022 was €70.51 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Advanced Oncotherapy's Book Value per Share for the quarter that ended in Jun. 2022 was €0.15. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Advanced Oncotherapy's Debt-to-Equity for the quarter that ended in Jun. 2022 was 0.99.

Advanced Oncotherapy Total Stockholders Equity Historical Data

The historical data trend for Advanced Oncotherapy's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy Total Stockholders Equity Chart

Advanced Oncotherapy Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Stockholders Equity

Get a 7-Day Free Trial

32.47

37.83

50.64

48.77

72.22

Advanced Oncotherapy Semi-Annual Data
	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
Total Stockholders Equity	Get a 7-Day Free Trial															55.10	48.77	42.28	72.22	70.51

Advanced Oncotherapy (FRA:R3I1) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Advanced Oncotherapy's Book Value per Share for the quarter that ended in Jun. 2022 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(70.51	-	0)	/	473.352
	=	0.15

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Advanced Oncotherapy's Debt-to-Equity for the quarter that ended in Jun. 2022 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(16.802	+	52.8)	/	70.51
	=	0.99

Advanced Oncotherapy Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Oncotherapy (FRA:R3I1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (FRA:R3I1) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Tenterden Street, Third Floor, London, GBR, W1S 1TE

Website

https://www.avoplc.com

Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.

Advanced Oncotherapy (FRA:R3I1) Headlines

No Headlines